- Home
- BATL vs MIRA Comparison
BATL vs MIRA Comparison
Compare BATL & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BATL
- MIRA
- Stock Information
- Founded
- BATL 1987
- MIRA 2020
- Country
- BATL United States
- MIRA United States
- Employees
- BATL N/A
- MIRA N/A
- Industry
- BATL Oil & Gas Production
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- BATL Energy
- MIRA Health Care
- Exchange
- BATL Nasdaq
- MIRA Nasdaq
- Market Cap
- BATL 20.6M
- MIRA 19.5M
- IPO Year
- BATL N/A
- MIRA 2023
- Fundamental
- Price
- BATL $1.33
- MIRA $1.37
- Analyst Decision
- BATL
- MIRA Strong Buy
- Analyst Count
- BATL 0
- MIRA 2
- Target Price
- BATL N/A
- MIRA $14.00
- AVG Volume (30 Days)
- BATL 18.1K
- MIRA 650.2K
- Earning Date
- BATL 05-14-2025
- MIRA 05-14-2025
- Dividend Yield
- BATL N/A
- MIRA N/A
- EPS Growth
- BATL N/A
- MIRA N/A
- EPS
- BATL N/A
- MIRA N/A
- Revenue
- BATL $191,498,000.00
- MIRA N/A
- Revenue This Year
- BATL N/A
- MIRA N/A
- Revenue Next Year
- BATL N/A
- MIRA N/A
- P/E Ratio
- BATL N/A
- MIRA N/A
- Revenue Growth
- BATL N/A
- MIRA N/A
- 52 Week Low
- BATL $1.05
- MIRA $0.51
- 52 Week High
- BATL $6.89
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- BATL 50.42
- MIRA 60.23
- Support Level
- BATL $1.32
- MIRA $1.29
- Resistance Level
- BATL $1.40
- MIRA $1.44
- Average True Range (ATR)
- BATL 0.05
- MIRA 0.11
- MACD
- BATL 0.00
- MIRA 0.00
- Stochastic Oscillator
- BATL 29.00
- MIRA 58.97
About BATL Battalion Oil Corporation
Battalion Oil Corp is an independent energy company focused on the acquisition, production, exploration, and development of onshore liquids-rich oil and natural gas assets in the U.S. Its properties and drilling activities are currently focused in the Delaware Basin.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.